Literature DB >> 22553577

Inhibition of corneal neovascularization by vascular endothelia growth inhibitor gene.

Hong Wang1, Bing Wang.   

Abstract

AIM: To evaluate the effect of Effectene™ lipofectine mediated plasmids encoding human pcDNA(4)-vascular endothelia growth inhibitor (pcDNA(4)-VEGI) gene on corneal neovascularization (CNV).
METHODS: Forty New Zealand albino rabbits were sutured by 5-0 silk on the superior cornea to induce CNV and divided into 4 random teams, ten per each team: team A: transfected by pcDNA(4)-VEGI gene mediated by Effectene(™) lipofectine transfection; team B: by plasmid pcDNA(4); team C: by Effectene(™), and team D: by normal saline. Length and area of CNV were observed under slit lamp every day after transfection. Immunohistochemistry was performed to detect the expression of VEGI protein in corneas at day 3, 7, 14 and 21.
RESULTS: 1) Average occurrence of CNV was 6.3 days in team A, 3.1 days in team B, 3.2 days in team C, and 3.2 days in team D. Difference was significant between A and other teams (P<0.01); 2) Length and average area of CNV in each period in team A was significantly different from those in team B, C and D (P<0.01); 3) VEGI expressions were observed in epithelium, stroma, endothelium and the cliff of CNV in team A at 3 days after transfection by immunohistochemical staining. None VEGI positive cells were found in the control teams (team B, C and D) all the time.
CONCLUSION: Effectene(™) lipofectine transfection technique can effectively transfect pcDNA(4)-VEGI gene into rabbit cornea and the length and CNV areas can be inhibited by VEGI gene.

Entities:  

Keywords:  corneal neovascularization; gene therapy; vascular endothelia growth inhibitor

Year:  2010        PMID: 22553577      PMCID: PMC3340739          DOI: 10.3980/j.issn.2222-3959.2010.04.04

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  12 in total

1.  Gene Transfer Technology in Therapy: Current Applications and Future Goals.

Authors: 
Journal:  Oncologist       Date:  1998

2.  Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes.

Authors:  J Crawford; B Wilkinson; A Vosnesensky; G Smith; M Garcia; H Stone; M L Perdue
Journal:  Vaccine       Date:  1999-05-04       Impact factor: 3.641

3.  Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor.

Authors:  J Yu; S Tian; L Metheny-Barlow; L J Chew; A J Hayes; H Pan; G L Yu; L Y Li
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

Review 4.  Progress in the use of adeno-associated viral vectors for gene therapy.

Authors:  Hildegard Büning; Markus Braun-Falco; Michael Hallek
Journal:  Cells Tissues Organs       Date:  2004       Impact factor: 2.481

5.  VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.

Authors:  V Haridas; A Shrivastava; J Su; G L Yu; J Ni; D Liu; S F Chen; Y Ni; S M Ruben; R Gentz; B B Aggarwal
Journal:  Oncogene       Date:  1999-11-11       Impact factor: 9.867

6.  Loss and restoration of immune privilege in eyes with corneal neovascularization.

Authors:  M R Dana; J W Streilein
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-11       Impact factor: 4.799

Review 7.  Ocular neovascularization: an epidemiologic review.

Authors:  P Lee; C C Wang; A P Adamis
Journal:  Surv Ophthalmol       Date:  1998 Nov-Dec       Impact factor: 6.048

Review 8.  Corneal neovascularization. Pathogenesis and inhibition.

Authors:  R J Epstein; R D Stulting; R L Hendricks; D M Harris
Journal:  Cornea       Date:  1987       Impact factor: 2.651

9.  Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.

Authors:  K B Tan; J Harrop; M Reddy; P Young; J Terrett; J Emery; G Moore; A Truneh
Journal:  Gene       Date:  1997-12-19       Impact factor: 3.688

10.  VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.

Authors:  Y Zhai; J Ni; G W Jiang; J Lu; L Xing; C Lincoln; K C Carter; F Janat; D Kozak; S Xu; L Rojas; B B Aggarwal; S Ruben; L Y Li; R Gentz; G L Yu
Journal:  FASEB J       Date:  1999-01       Impact factor: 5.191

View more
  3 in total

Review 1.  An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Authors:  Chenchen Zhang; Yuan Yin; Jing Zhao; Yanxia Li; Yuanping Wang; Zhaoying Zhang; Lingzhi Niu; Yajuan Zheng
Journal:  Int J Nanomedicine       Date:  2022-10-19

Review 2.  Strategies for local gene therapy of corneal allograft rejection.

Authors:  Pho Nguyen; Samuel C Yiu
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar

3.  TNFSF15 Inhibits Blood Retinal Barrier Breakdown Induced by Diabetes.

Authors:  Feng Jiang; Qingzhong Chen; Liming Huang; Ying Wang; Zhuhong Zhang; Xiangda Meng; Yuanyuan Liu; Chunjie Mao; Fang Zheng; Jingkai Zhang; Hua Yan
Journal:  Int J Mol Sci       Date:  2016-04-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.